Oculis Appoints Ding Weibo as Global Chief Operating Officer and General Manager for China

One month ago, the news broke that Mr. Ding Weibo, President of Fresenius Kabi China, would be leaving his position on February 1, 2022, to pursue external development opportunities.

Ding Weibo, as a well-known executive in the industry, his whereabouts are naturally widely followed.

On January 5, Oculis announced the appointment of Wei Bo Ding as Global Chief Operating Officer (COO) and General Manager of China, leading Oculis' global operations and business development in China, effective from February 1, 2022.

As an influential and well-known senior executive in the industry, Ding Weibo's career has spanned several multinational pharmaceutical companies, including Bristol-Myers Squibb, Xian Janssen, Novartis China, and Fresenius Kabi. It is reported that after joining Oculis, Ding Weibo will be based at the Oculis Hong Kong office.

Note: The original text has been abridged.